The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 24, 2020
Filed:
May. 06, 2016
Janssen Biotech, Inc., Horsham, PA (US);
Glenn Anderson, Spring House, PA (US);
Rosa Cardoso, Spring House, PA (US);
Michael Diem, Spring House, PA (US);
Francois Gaudet, Spring House, PA (US);
Shalom Goldberg, Spring House, PA (US);
Benjamin Harman, Spring House, PA (US);
Linus Hyun, Spring House, PA (US);
Steven Jacobs, Spring House, PA (US);
Donna Klein, Spring House, PA (US);
Yingzhe Li, Spring House, PA (US);
Jinquan Luo, Spring House, PA (US);
Ronan McDaid, Spring House, PA (US);
Jill Mooney, San Diego, CA (US);
Jennifer Nemeth-Seay, Spring House, PA (US);
Karyn O'Neil, Spring House, PA (US);
Steven Pomerantz, Spring House, PA (US);
Galla Chandra Rao, Spring House, PA (US);
Tracy Spinka-Doms, Spring House, PA (US);
Alexey Teplyakov, Spring House, PA (US);
Leopoldo Luistro, Spring House, PA (US);
Sheng-Jiun Wu, Spring House, PA (US);
Janssen Biotech, Inc., Horsham, PA (US);
Abstract
Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.